{"metadata":{"topics":["2nd millennium introductions","Accountability","Accounting","Adoption","Applied ethics","Asset","Balance sheet","Banking","Behavioural sciences","Board of directors","Broker","Business","Business economics","Business law","Business organizations","Cash","Cash and cash equivalents","Choice of law","Civil law (common law)","Civil law (legal system)","Committee","Common law","Common stock","Companies","Company","Comparative law","Consolidation (business)","Constitutional law","Consultant","Contract","Contract law","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporation","Corporations","Corporatism","Creditor","Culture","Debt","Delaware","Delaware General Corporation Law","Derivatives (finance)","Disability","Dividend","Documents","Economic law","Economics","Economies","Economies of Europe","Economy","Economy of the United States","Employee benefits","Employee relations","Employment","Equity securities","Ethical principles","European Union member economies","Exercise","Factor income distribution","Fair market value","Family economics","Fiduciary","Finance","Financial accounting","Financial economics","Financial law","Financial markets","Financial services","Fundamental analysis","GlaxoSmithKline","Good faith","Governance","Government","Government agencies","Government finances","Government information","Government of the United States","Holding company","Household income","Human activities","Human resource management","Incentive","Income","Independent contractor","Industries","Intellectual works","Interest","Internal Revenue Code","International law","Interpersonal relationships","Investment","Jargon","Justice","Labor","Law","Law and economics","Law of obligations","Leadership","Legal concepts","Legal documents","Legal ethics","Legal fictions","Legal literature","Legal writing","Liquidation","Love","Management","Market (economics)","Market value","Marketplace","Mergers and acquisitions","Microeconomics","Money","Morality","NASDAQ","Natural resources law","Number","Official documents","Open government","Option (finance)","Options (finance)","Ownership","Paragraph","Parent","Payment","Payments","Pennsylvania","Percentage","Personal finance","Personality traits","Philosophy","Political economy","Political ideologies","Political science","Politics","Politics of the United States","Present value","Price","Principles","Private law","Promissory note","Property","Property law","Public administration","Public finance","Public law","Public policy","Public sphere","Real estate","Regulation","Regulatory compliance","Restricted stock","Retirement","Revenue","Rights","Roman law","Rules","Sales","Section 31","Securities (finance)","Securities Exchange Act of 1934","Securities market","Security (finance)","Service industries","Services (economics)","Share (finance)","Shareholder","Social institutions","Social policy","Sociological theories","Statutory law","Stock","Stock certificate","Stock market","Subsidiary","Suffrage","Table of contents","Tax","Taxation","Tender offer","The Wall Street Journal","Treasury stock","Trustee","U.S. Securities and Exchange Commission","United States","United States economic policy","United States federal policy","United States law","Urban, rural, and regional economics","Valuation (finance)","Value (ethics)","Vesting","Virtue","Wall Street","Withholding tax","Working conditions","World economy"],"person_names":[],"vars":{},"organization_names":["change in control","exercise price","glaxo group","glaxosmithkline plc","gsk","gsk change in control","inc.","nasdaq","nso","smithkline beecham","theravance","theravance, inc."],"agreement_id":"9b0f2669f730f52d122eb7970f06e66d2b8197fcb733e1d8473bf9dab133c314","terms":["**(AS AMENDED DECEMBER 16, 2009)**","**(AS AMENDED [[Date 4: Date]])**","**,**","**Cumulative Number of Shares**","**Date of Board/Committee Approval**","**EXHIBIT A**","**Number of Shares Added**","**Page**","**SCHEDULE OF SHARES RESERVED FOR ISSUANCE UNDER THE PLAN**","**TABLE OF CONTENTS**","**THERAVANCE, INC. 2008 NEW EMPLOYEE EQUITY INCENTIVE PLAN (AS ADOPTED EFFECTIVE [[Date 1: Date]])**","**THERAVANCE, INC. 2008 NEW EMPLOYEE EQUITY INCENTIVE PLAN**","**not**","“**Affiliate**”","“**Award**”","“**Board**”","“**Change in Control**”","“**Code**”","“**Committee**”","“**Common Share**”","“**Consultant**”","“**Corporation**”","“**Employee**”","“**Exchange Act**”","“**Exercise Price**","“**Fair Market Value**”","“**NSO**”","“**Option**”","“**Optionee**”","“**Parent**”","“**Participant**”","“**Plan**”","“**Restricted Share**”","“**Restricted Stock Agreement**”","“**Service**”","“**Stock Option Agreement**”","“**Stock Unit Agreement**”","“**Stock Unit**”","“**Subsidiary**”","“GSK”","“Governance Agreement”","“Original Directors”"]}}